Syntimmune has revealed that it has brought in a new CEO to begin the new year, with the appointment of Jean-Paul Kress. He leaves behind his position as EVP, President International and Head of Global Therapeutic Operations at Biogen, after only eight months in the position, to take the helm.
Ook interessant voor je
Reageer